2 weeks Ago By Moneycontrol
Shares of Syngene International Ltd. tumbled 10% on Thursday, April 24, 2025 as the company announced 3% year-on-year decline in consolidated net profit to Rs 183 crore for Q4 FY25, down from Rs 189 crore in the same period last year. Total income for the quarter rose to Rs 1,037 crore, compared to Rs 933 crore a year earlier.
For the full fiscal year, Syngene reported a net profit of Rs 496 crore, a decrease from Rs 510 crore in FY24, with total income increasing to Rs 3,714 crore from Rs 3,579 crore. The company's cautious guidance for FY26 further unsettled investors. CFO Deepak Jain noted that EBITDA margins may moderate to the mid-twenties, with a potential year-on-year decline in profit after tax.
The stock's decline also reflects broader concerns over the company's performance amid a challenging global biotech funding environment. Despite the downturn, Syngene highlighted strategic initiatives, including the acquisition of a state-of-the-art biologics manufacturing facility in the U.S.
, aimed at strengthening its position in the biologics contract development and manufacturing organization (CDMO) sector. Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management.
Moneycontrol.com advises users to check with certified experts before taking any investment decisions..
